Low urgency

UPDATE: Hintermann Series H3 Total Ankle Replacement Has a Higher-Than-Expected Risk of Device Failure: FDA Safety Communication

Detected July 6, 2026 · in Med-Spa & Aesthetics Clinics

FDA warns that Hintermann Series H3 Total Ankle Replacement has higher-than-expected failure risk. While not directly related to med-spa services, clinics offering orthopedic procedures should review patient communications and device monitoring.

Aforeworn detected this change in the Med-Spa & Aesthetics Clinics space on July 6, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Low urgency. Med-spa clinics that perform or refer for total ankle replacement procedures should confirm how it applies to their specific situation before acting. There is a time constraint attached: Ongoing; no specific deadline but prompt action advised. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Med-Spa & Aesthetics Clinics continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.

What changed

FDA updated safety communication indicating increased failure risk for Hintermann Series H3 TAR

Who it affects

Med-spa clinics that perform or refer for total ankle replacement procedures

What you must do

Review inventory for Hintermann Series H3 devices; inform affected patients; follow FDA recommendations

Deadline

Ongoing; no specific deadline but prompt action advised

Source: http://www.fda.gov/medical-devices/safety-communications/update-hintermann-series-h3-total-ankle-replacement-has-higher-expected-risk-device-failure-fda

Never miss a change like this again

Aforeworn watches Med-Spa & Aesthetics Clinics around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.

Start your free trial

Related changes in Med-Spa & Aesthetics Clinics